<?xml version="1.0" encoding="UTF-8"?>
<p>Given the host inflammatory response to SARS-CoV-2, immune-based therapy is recommended for the treatment of moderate to severe cases of COVID-19 [
 <xref rid="B123-viruses-12-01039" ref-type="bibr">123</xref>]. Immunomodulatory agents are used as therapy for dysregulated innate immune responses to SARS-CoV-2 infection. Currently recommended agents include corticosteroids, interleukin inhibitors, IFNs, and tyrosine kinase inhibitors [
 <xref rid="B123-viruses-12-01039" ref-type="bibr">123</xref>,
 <xref rid="B125-viruses-12-01039" ref-type="bibr">125</xref>,
 <xref rid="B126-viruses-12-01039" ref-type="bibr">126</xref>]. In clinical trials, combination therapies are used for the treatment of COVID-19. For instance, patients treated with a triple combination of IFNÎ²-1b, lopinavir-ritonavir, and ribavirin showed faster viral clearance and more rapid clinical improvement compared with the control group [
 <xref rid="B127-viruses-12-01039" ref-type="bibr">127</xref>]. A summary of the action of these agents against SARS-CoV-2 infection is shown in 
 <xref rid="viruses-12-01039-t001" ref-type="table">Table 1</xref>.
</p>
